Vliyanie antigipertenzivnoy terapii na aktivnost' adipokinov i endotelina-1 u bol'nykh arterial'noy gipertoniey s ozhireniem
https://doi.org/10.14341/2071-8713-4949
Abstract
The aim of the study was to investigate the pharmacodynamic characteristics of the modern antihypertensive therapy in obese hypertensive patients. Materials and methods. The activity of leptin, adiponectin and endothelin-1 and cardiohemodynamics were studied in 61 patients with essential hypertension and obesity (body mass index 34,3±4,8 kg/m2) before and after the 12-weeks treatment with zofenopril (n=31) and nebivolol (n=29). Results. It was revealed that obese hypertensive patients had abnormal circadian profile of blood pressure (63.9%), hyperleptinemia together with the decrease of the adiponectin activity (67%), as well as the increased activity of endothelin-1 (54%). The 12-weeks therapy with zofenopril and nebivolol has resulted in the improvement of the daily profile of the arterial pressure with the achievement of the target level of the arterial pressure in 72% and 79% of patients correspondingly. The following was recorded: the decrease in the activity of leptin and endothelin-1 in both groups; upward trend of the adiponectins activity under the influence of zofenopril. Conclusion. Zofenopril and nebivolol in obese hypertensive patients in addition to the antihypertensive action reduce negative cardiometabolic effects of the activation of adipocytes and endothelin-1.
About the Authors
S Oshorova
Sechenov First Moscow State Medical Unovarsity
Russian Federation
Russian Federation
Tatyana Romantsova
Sechenov First Moscow State Medical Unovarsity
Russian Federation
Russian Federation
T Morozova
Sechenov First Moscow State Medical Unovarsity
Russian Federation
Russian Federation
References
1. Беляева О.Д., Баженова Е.А., Березина А.В. и др. Уровень адипонектина, показатели липидного и углеводного обменов у пациентов с абдоминальным ожирением // Артериальная гипертензия. - 2009. - Т. 15, №3. - С. 309-314.
2. Диагностика и лечение артериальной гипертензии // Кардиоваскулярная те- рапия и профилактика. - 2008. - № 7(6), Приложение 2.
3. Кобалава Ж.Д., Виллевальде С.В., Исикова Х.В. Роль адипонектина в развитии и прогрессировании сердечно-сосудистых заболеваний // Кардиология. - 2009. - №1. - С. 51-58.
4. Недогода С.В., Барыкина И.Н., Чаляби Т.А. и др. Ожирение и артериальная гипертензия. Часть II: особенности антигипертензивной терапии при ожирении // Кардиоваскулярная терапия и профилактика. - 2009. - №8 (1). - С. 88-98.
5. Ожирение: этиология, патогенез, клинические аспекты / Под ред. И.И. Дедова, Г.А. Мельниченко. - М.: ООО «Медицинское информационное агентство», 2006. - 456с.
6. Adamczak M., Wiecek A., Funahashi T. et al. Decreased plasma adiponectin concentration in patients with essential hypertension // Am J Hypertens. - 2003. - Vol. 16, №1. - P. 72-75.
7. Berg A.N., Scherer P.E. Adipose tissue, inflammation, ad cardiovascular disease // Circ Res. - 2005. - Vol. 96, №9. - P. 939-949.
8. Dyer A.R. et al. Body mass index versus height and weight in relation to blood pressure. Finding for the 10,079 persons in the INTERSALT Study // Am J Epidemiol. - 1990. - Vol. 131. - P. 589-596.
9. Fantuzzi G. Adipose tissue, adipokines, and inflammation // J Allergy Clin Immunol. - 2005. - Vol. 115, №5. - P. 911-919.
10. Hall J., Zappe D., Alonso-Galicia M. et al. Mechanism of obesity-induced hypertension // News Physiol Sci. - 1996. - Vol. 11. - P. 255-261.
11. Hall J.E., Brands M.W., Hildebrandt D.A. Role of sympathetic nervous system and neuropeptides in obesity hypertension // Braz J Med Biol Res. - 2000. - Vol. 33. - P. 605-618.
12. Haynes W.G. Role of leptin in obesity-related hypertension // Exp Physiol. - 2005. - Vol. 90(5). - P. 683-688.
13. Hubert H.B., Feinleib M., McNamara P.M. et al. Obesity as an independent risk factor for cardiovascular disease: a 26 year follow-up of participants in the Framingham heart study // Circulation. - 1983. - Vol. 67. - P. 968-977.
14. Iwashima Y., Katsuya T., Ishikawa K. Hypoadiponectinemia is an independent risk factor for hypertension // Hypertension. - 2004. - Vol. 43. - P. 1318-1323.
15. Mather K.J., Mirzamohammadi B., Lteif A. et al. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes // Diabetes. - 2002. - Vol. 51. - P. 3517-3523.
16. Messerli F.H., Christie B., DeCarvalho J.D. et al. Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity // Arch Intern Med. - 1981. - Vol. 141. - P. 81-85.
17. Mokdad A.N., Serdula M.K., Dietz W.H. et al. The spread of the obesity epidemic in the United States, 1991-1998 // JAMA. - 1999. - Vol. 282. - P. 1519-1522.
18. Obesity - preventing and managing the global epidemic: WHO Technical Report Series 894. - Geneva, 2000.
19. Scherer P.E. Adipose tissue: from lipid storage compartment to endocrine organ // Diabetes. - 2006. - Vol. 55. - P. 1537 1545.
20. Yusuf S., Hawken S. Ounpuu S. et. al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study // Lancet. - 2004. - Vol. 364 (Issue 9438). - P. 937 952.
Review
For citations:
, , Vliyanie antigipertenzivnoy terapii na aktivnost' adipokinov i endotelina-1 u bol'nykh arterial'noy gipertoniey s ozhireniem. Obesity and metabolism. 2011;8(2):26-31. (In Russ.) https://doi.org/10.14341/2071-8713-4949
Views:
511
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
